Literature DB >> 10543935

IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells.

J G Jackson1, D Yee.   

Abstract

IGF-responsive breast cancer cells activate insulin receptor substrate (IRS)-1 after IGF-I treatment. To determine if IRS-1 expression was sufficient to enable IGF-responsiveness, two IGF-I unresponsive breast cancer cell lines (MDA-MB-435A and MDA-MB-468) were transfected with IRS-1. While IGF-I caused tyrosine phosphorylation of IRS-1 in both transfected cell lines, increased MAP kinase activity was not seen. IGF-I treatment of 435A IRS-1 transfected cells resulted in minimal increased PI3 kinase activity associated with IRS-1, while IRS-2/PI3 kinase was greatly reduced. In MDA-MB-468 IRS-1 transfected cells, IGF-I caused increased IRS-1 associated PI3 kinase activity compared to parental cells, but at levels far below those observed in IGF-responsive MCF-7 cells. The transfected cells were also not responsive to IGF-I in monolayer growth. Thus, IRS-1 expression and activation alone are insufficient to mediate a proliferative response to IGF-I in breast cancer cells, and it is likely that maximal activation of downstream signaling pathways must also occur. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543935     DOI: 10.1054/ghir.1999.0113

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  9 in total

1.  Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.

Authors:  Xudong Tang; Qunzhou Zhang; Shihong Shi; Yun Yen; Xiangyong Li; Yuefei Zhang; Keyuan Zhou; Anh D Le
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

2.  Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells.

Authors:  Jose Mercado-Matos; Jennifer L Clark; Andrew J Piper; Jenny Janusis; Leslie M Shaw
Journal:  J Biol Chem       Date:  2017-03-20       Impact factor: 5.157

3.  The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.

Authors:  Marc A Becker; Yasir H Ibrahim; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Endocrinol       Date:  2011-02-03

4.  Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.

Authors:  Yasir H Ibrahim; Sara A Byron; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

5.  WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.

Authors:  Celina G Kleer; Yanhong Zhang; Quintin Pan; Sofia D Merajver
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

6.  Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.

Authors:  Zoë Davison; Gail E de Blacquière; Bruce R Westley; Felicity E B May
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

7.  Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

Authors:  S A Byron; K B Horwitz; J K Richer; C A Lange; X Zhang; D Yee
Journal:  Br J Cancer       Date:  2006-10-17       Impact factor: 7.640

8.  Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival.

Authors:  Crystal A Tonnessen-Murray; Wesley D Frey; Sonia G Rao; Ashkan Shahbandi; Nathan A Ungerleider; Joy O Olayiwola; Lucas B Murray; Benjamin T Vinson; Douglas B Chrisey; Christopher J Lord; James G Jackson
Journal:  J Cell Biol       Date:  2019-09-17       Impact factor: 10.539

9.  Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling.

Authors:  J Lackey; J Barnett; L Davidson; I H Batty; N R Leslie; C P Downes
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.